UK Avoids 'Cliff Edge' By Extending EU Drug Approval Reliance Procedure
Executive Summary
The UK drugs regulator says it needs to make sure that companies do not “deprioritize” GB approval applications while a new “international reliance framework” is being developed.
You may also be interested in...
£10m Cash Boost For UK Regulator To Speed Up New Drug Approvals
An injection of new money should provide something of a shot in the arm for the UK’s drugs regulator as it deals with post-Brexit realities.
UK Prepares For New International Regulatory Reliance Framework
From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.
Brexit: ‘Enormous Complexity’ And ‘Significant Challenges’ Laid Bare
Speakers at a conference organized in Dublin by the Parenteral Drug Association spoke of the havoc wrought by the UK’s departure from the EU, and described how one company took steps to prepare for a no-deal Brexit, according to Ruaidhri O’Brien, who attended the event.